New strategy aims to tame harsh side effects of cancer immunotherapy
NCT ID NCT07237594
Summary
This study is testing if a drug called secukinumab can help patients with advanced melanoma safely restart a powerful type of cancer treatment called immunotherapy. It focuses on patients who had to stop their previous immunotherapy due to serious side effects like severe skin rash or liver inflammation. The goal is to see if giving secukinumab before and during the restart of immunotherapy can help control these side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.